Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 1,595,226 |
|
|||||
| News | - | ||||||
| Day High | 7.51 | Low High |
|||||
| Day Low | 7.25 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Altimmune Inc | ALT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.0502 | 0.69% | 7.3502 | 19:54:49 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.38 | 7.25 | 7.51 | 7.36 | 7.30 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 12,937 | 1,595,226 | $ 7.35 | $ 11,727,502 | - | 2.09 - 14.84 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:54:49 | formt | 1,190 | $ 7.3502 | USD |
Altimmune (ALT) Options Flow Summary
Altimmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 395.44M | 53.73M | - | 426k | -88.45M | -1.65 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Altimmune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.86 | 7.63 | 6.282 | 6.82 | 3,386,079 | 0.4902 | 7.15% |
| 1 Month | 9.09 | 9.15 | 6.282 | 7.36 | 2,970,786 | -1.74 | -19.14% |
| 3 Months | 10.44 | 14.84 | 6.282 | 9.76 | 4,624,172 | -3.09 | -29.60% |
| 6 Months | 2.70 | 14.84 | 2.315 | 8.00 | 7,918,260 | 4.65 | 172.23% |
| 1 Year | 4.95 | 14.84 | 2.09 | 7.27 | 4,696,272 | 2.40 | 48.49% |
| 3 Years | 13.14 | 23.49 | 2.09 | 8.86 | 2,574,816 | -5.79 | -44.06% |
| 5 Years | 2.85 | 35.10 | 1.45 | 10.12 | 2,154,067 | 4.50 | 157.90% |
Altimmune Description
| Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). |
